TriSalus Life Sciences, Inc. last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $11.4 million (+1.7% year over year) and diluted EPS of -$0.16. It usually reports 12–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 13, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
11
+1.7%
|
-9
-10.8%
|
-0.16
+40.7%
|
|
May 12, 2026
42 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
9
-2.9%
|
2
+114.8%
|
0.03
+107.7%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
13
+59.8%
|
-10
+3.5%
|
-0.21
+47.4%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
12
+57.4%
|
-11
-350.6%
|
-0.96
-700.0%
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
11
+52.3%
|
-8
-91.3%
|
-0.27
-28.6%
|
|
Apr 30, 2025
30 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
9
+42.0%
|
-10
+21.4%
|
-0.39
+35.0%
|
|
Jan 23, 2025
23 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
8
+44.4%
|
-10
+71.6%
|
-0.40
+74.9%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
7
+41.5%
|
-2
-68.4%
|
-0.12
+14.3%
|
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- TLSI (Nasdaq), TLSIW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westminster, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1826667
- Former names
- MedTech Acquisition Corp (until Aug 10, 2023); MedTech Acquisition Corporation (until Oct 29, 2020)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.